ELTX Elicio Therapeutics
- 3.680
- +0.290+8.55%
Elicio Therapeutics News
Elicio Therapeutics Shares Drop 35% After Public Offering Prices
By Chris Wack Elicio Therapeutics shares fell after an underwritten public offering with proceeds of up to $11.5 million priced at $5 a unit. The clinical-stage biotechnology company's stock was dow
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
Thursday, Elicio Therapeutics Inc (NASDAQ:ELTX) released new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-
Elicio Therapeutics to Place With Certain Investors in Lieu of Common Stock Up to 1.8M Shares at $5 a Share >ELTX
Elicio Therapeutics to Place With Certain Investors in Lieu of Common Stock Up to 1.8M Shares at $5 a Share >ELTX
Elicio Therapeutics to Use Net Proceeds for the Advancement of Development Pipeline >ELTX
Elicio Therapeutics to Use Net Proceeds for the Advancement of Development Pipeline >ELTX
Express News | Elicio Therapeutics Prices $11.5M Underwritten Public Offering Of 500,000 Shares And Accompanying Common Warrants At $5.00/Share And Accompanying Common Warrant
Express News | Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
Sector Update: Health Care Stocks Higher Pre-Bell Friday
Health care stocks were gaining pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) up 0.4%. Carisma Therapeutics (CARM) said late Thursday that
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell
US stock futures are trending modestly higher in premarket activity Friday as investors await the results of the latest reading of the personal consumption expenditure price index, a key inflation mea
Top Premarket Decliners
Nexalin Technology (NXL) shares were down nearly 37% in recent Friday premarket activity after the company said overnight that it priced a public offering of its 3 million common shares at $1.75 apiec
Express News | Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median...
Express News | Elicio Therapeutics Inc - to Use Proceeds for Development Pipeline
Express News | Elicio Therapeutics Announces Proposed Public Offering
Express News | Elicio Therapeutics Announces Prelim. Disease-Free Survival Analysis From Phase 1a Study Of ELI-002 7P Showing Patients Receiving ELI-002 7P At Dose Of 4.9mg AMP-Peptide Were Yet To Reach Midian DFS Endpoint As Of May 24 Cutoff Date
Express News | Elicio Therapeutics Inc - Providing Additional Clinical Data Updates From Amplify Phase 1 Trials Expected Later in 2024
Express News | Elicio Therapeutics Announces Preliminary Disease-Free Survival Analysis From the Ongoing Amplify-7P Phase 1a Study of Eli-002 7P
Elicio Therapeutics Reports Inducement Grants
BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the
Express News | Elicio Therapeutics Inc - Sales Agreement Prospectus Covering Offering of up to $40 Mln of Common Stock That May Be Issued and Sold From Time to Time
Express News | Elicio Therapeutics Inc Files for Mixed Shelf of up to $200 Mln – SEC Filing
Elicio Therapeutics On May 23 Announced Preliminary Data From Ongoing AMPLIFY-7P Phase 1a Study Of ELI-002 7P In Patients With MKRAS-Driven Solid Tumors At 2024 ASCO Annual Meeting
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T cel
Express News | Elicio Therapeutics: Eli-002 7P Was Well Tolerated With T Cell Responses Correlating With a Reduction in Tumor Biomarkers at Recommended Phase 2 Dose
Analysis
Price Target
No Data
